British American Tobacco (BATS) Trading Update summary
Event summary combining transcript, slides, and related documents.
Trading Update summary
31 Jan, 2026Leadership and Strategic Priorities
New CFO Soraya Benchikh rejoined, bringing extensive global and financial experience.
Focus on managing multi-category business complexity and driving balanced top and bottom line growth.
Strategic agenda emphasizes quality growth, sustainable results, and enhanced shareholder returns.
Financial Performance and Outlook
On track to meet FY24 guidance, expecting low single-digit organic revenue and adjusted profit growth in 2024, with stronger H2 performance due to innovation, inventory phasing, and U.S. commercial actions.
H1 revenue and adjusted profit expected to decline by low single digits due to U.S. investments and macro pressures.
Group cigarette volume share in key markets up 30 bps, with robust pricing and share gains in AME and APMEA.
Technical guidance includes a global tobacco industry volume decline of ~3% and a c.2% transactional FX headwind.
Category and Regional Highlights
New categories now deliver over £3bn in revenue and are profitable two years ahead of target.
Premium segment in U.S. shows sequential volume share improvement, with Lucky Strike as the fastest-growing brand.
EMA and APMEA regions deliver robust pricing and share gains, with key markets including Germany, Romania, Pakistan, and Mexico.
Group cigarette volume share in key markets up 30 bps.
Latest events from British American Tobacco
- Revenue up 2.9%, New Categories up 18%, adjusted EPS up 7.9%, FY26 guidance reaffirmed.BATS
H1 2026 - Mid-teens revenue growth led by Modern Oral and Vapour, with robust U.S. and cash generation momentum.BATS
Trading update - Accelerating smokeless transformation and U.S. growth through innovation and regulatory action.BATS
Consumer Analyst Group of New York Conference (CAGNY) 2026 - FY25 delivered top-end results, led by Modern Oral and New Category growth, strong U.S. and AME performance.BATS
H2 2025 - H1 revenue up 1.8% at constant FX, led by Modern Oral and U.S. growth; profit up 19.1%.BATS
H1 2025 - Accelerates smokeless transformation, targeting >50% revenue from new categories by 2035.BATS
CMD 2024 - New Category growth and innovation offset U.S. headwinds, supporting full-year guidance.BATS
H1 2024 - Accelerating innovation and smokeless growth, with robust financials and U.S. market stabilization.BATS
21st Annual dbAccess Global Consumer Conference 2024 - New category growth and cost discipline offset regulatory and illicit trade headwinds in 2024.BATS
H2 2024